drugset / Trial / NCT01114880

Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis

NCT01114880

Phase 3 Completed 344 enrolled Abbott
RandomizedParallel-groupTriple-blindTreatment

Summary

Study of the efficacy and safety of adalimumab compared with placebo in adult Chinese participants with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal anti-inflammatory drugs (NSAIDs)

Timeline

Start
2010-01
Primary completion
2010-09
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous